The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor, Lenka; Rulten, Stuart L; Cranston, Aaron N; Odedra, Rajesh; Brown, Henry; Jaspers, Janneke E; Jones, Louise; Knights, Charlotte; Evers, Bastiaan; Ting, Attilla; Bradbury, Robert H; Pajic, Marina; Rottenberg, Sven; Jonkers, Jos; Rudge, David; Martin, Niall M B; Caldecott, Keith W; Lau, Alan; O'Connor, Mark J

Oplustil O'Connor, Lenka; Rulten, Stuart L; Cranston, Aaron N; Odedra, Rajesh; Brown, Henry; Jaspers, Janneke E; Jones, Louise; Knights, Charlotte; Evers, Bastiaan; Ting, Attilla; Bradbury, Robert H; Pajic, Marina; Rottenberg, Sven; Jonkers, Jos; Rudge, David; Martin, Niall M B; Caldecott, Keith W; Lau, Alan; O'Connor, Mark J.

Affiliation

Oplustil O'Connor L; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
Rulten SL; Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, United Kingdom.
Cranston AN; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
Odedra R; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
Brown H; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
Jaspers JE; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jones L; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
Knights C; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
Evers B; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ting A; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
Bradbury RH; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
Pajic M; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rottenberg S; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Rudge D; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
Martin NM; KuDOS Pharmaceuticals Ltd, Cambridge, United Kingdom.
Caldecott KW; Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, United Kingdom.
Lau A; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
O'Connor MJ; AstraZeneca, Alderley Park, Macclesfield, United Kingdom. mark.j.oconnor@astrazeneca.com.

Cancer Res ; 76(20): 6084-6094, 2016 10 15.

Article de En | MEDLINE | ID: mdl-27550455

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Phtalazines / Pipéridines / Poly(ADP-ribose) polymerases / Inhibiteurs de poly(ADP-ribose) polymérases / Tumeurs expérimentales Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Cancer Res Année: 2016 Type de document: Article Pays d'affiliation: Royaume-Uni

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links